Patent 11638711 was granted and assigned to MC2 Therapeutics Limited on May, 2023 by the United States Patent and Trademark Office.
The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase,